Futura Medical Share Price (FUM)

"bignose58"

You raise some interesting points re: Eroxon for women:

!. "What I am interested to know is how it would work on women since their parts can be much smaller than men's"

Actually, the female genitalia are about the same size as in males. The erectile tissue does not protrude as it does in men, it remains hidden internally. All of this erectile tissue needs to become swollen as it fills with blood in response to stimulation. As blood moves into the pelvic bowl it causes the va*ginal canal to lengthen and widen. Nitric oxide is also implicated in the lubrication response which is also necessary for women's sense of comfort during intercourse.

2. "Surely there would need to be some additional "active" ingredient as I think women's stimulation requirements are a lot more complex and certainly need a lot more than just more blood in the nether regions.?".

Yes you are right, blood is not sufficient to complete the entire "puzzle". Eroxon also has an effect on excitatory neurotransmitters in the thousands of nerve endings within the erectile tissue. These nerve endings send pleasure impulses into the brain. Eroxon will amplify the pleasure impulses that women perceive. Researchers have not even managed to work out which neurotransmitters are implicated, so it would have been impossible to design a drug for this issue: Eroxon was indeed a lucky break for Futura.

3."It seems to me for a woman's product to be viable, a lot more understanding on both physical and mental stimulation will be needed."

Futura are not aiming to unravel all of the psychological and social (pychosocial) mysteries behind female sexual dysfunction. Futura will probably try to avoid women with obvious pychosocial issues in their clinical studies. Contemporary researchers have a good understanding of the nerve endings involved in sexual pleasure for women so Futura will have access to that knowledge.

4. "Of course, anyone actually achieving such a product would hit the jackpot (more so than any erectile product)"

Achieving this product has now become Futura's highest priority.

aimo dyor

According to our FD, the company is now covered by 3 brokers: Trinity Delta, Liberum and Stifel Nicolaus. Respectively, their current valuations for Futura are 121p, 131p, and 125p per share.

Closing market price tonight? 36p.

With c 301m shares in issue, the company is undervalued by the best part of £300m. That’s a whopping amount.

Part of this undervaluation is due to the company being valued on a marginal rather than an average basis. Marginal sellers are ‘happy’ to sell at 36p, because no buyers are currently offering prices in line with analysts’ estimates. But Lombard, which owns just under 30% of the shares will not be a marginal seller if the company is eventually sold. As well, Futura’s executives would point to analysts estimates and say they have a fiduciary duty to seek at least as much as £1.20 a share to agree a sale of the company.

Part of the undervaluation is also due to marginal buyers being unduly influenced by anonymous reviews rather than by solid science. As an example of dodgy reviews, look at https://www.yell.com/biz/pro-energy-ltd-romford-9879988/#:~:text=Pro%20Energy%20team%20was%20on,Pro%20Team%20for%20similar%20work. 145 reviews, 4.9/5 rating. Good eh?

Look again. Look at the names behind the reviews. Anything seem strange? How many are written by eg people called Muhammad? Or are simply Asian?

Unfortunately, too many private investors on this board agonise over information they have easy access to - eg product reviews for Eroxon - rather than seeing beyond the many manufactured reviews to the solid science underpinning Eroxon. Science approved by the EU and FDA, supported by in-house research by Cooper, and which global companies worth billions of dollars are prepared to back with their money. There are now many AI tools that will write bad product reviews. Amazon itself has lots of misleading reviews, attached to the wrong product or, as I have experienced, sellers offering financial inducements to buyers to give a 5 star review for a product that is in reality just plain poor.

These are not the only reasons for the undervaluation. Eroxon is a completely new product, so has imponderables about roll out, penetration, and repeat take-up, for example. Futura has always emphasised the key importance of the US market. Launch there will immediately transform the company into a profit-making one. I would like to see more institutions invested in Futura. Not because that would influence my decision to buy the shares, but rather to have more of the shares owned by professional investors, who see the true value of the science, rather than the private investors on here who agonise over bunkum, or try to get others to buy or sell according to their own trading strategies.

At the moment, the tail is wagging the dog. I hope the actual launch of Eroxon in the US will enable the dog to finally start to control its tail.

Never ever expected SP to be at this point, seems mad that anyone can get onboard and almost guarantee a 300% increase within 24month or maybe earlier? So much for the get in early to reap the rewards and the so called long term investment! Investors who have jumped in & out have made a fortune and the late arrivals to the party will see gains with little time invested. I see RNS’s being released all the time to bump up the SP, only for a fund raise soon after! FUM have done it in the past as well! Yet they can’t be bothered to release RNS’s now and can’t even give a decent financial forecast JOKE! Please someone buy these morons out discard the current BOD.

Https://www.proactiveinvestors.co.uk/companies/news/1045682/futura-medical-shares-worth-125p-says-us-investment-bank-1045682.html

Think they need to get the male version over the line first & generate some returns for shareholders. They had several potential products like TPR100 pain relief, spent millions and told us all the commercial potential was massive, they were actually working on the final stages! Now just dropped it & thats fine but Eroxon still needs to prove itself in the biggest market of all, as does the Brand Eroxon! all those negative reviews need addressing as not being followed up with positives even now a year on! Something else they have no control over but need to do something about before extending the range.